retatrutide phase 2 weight loss a 9-week trip on — LessWrong Retatrutide—A Game Changer in Obesity

For UK patients, the most accurate expectation is: watch for approvals and rollout news in 2026 , but plan for realworld access to depend on MHRA decisions, supply, and NHS commissioning pathways

However, tirzepatide also has low efficacy to induce GLP-1R internalisation, perhaps by its limited ability to recruit -arrestin

Pending successful completion, FDA approval could come as early as 2027, which would make retatrutide the first approved triple-agonist medication

Fact: Food Increases GLP-1 GLP-1 is important for appetite regulation

Many authors are mistaken when comparing trial results

Dysbiosis of human gut microbiome in young-onset colorectal cancer